Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107603 | 0.90 | KMT2A (0.32) | KMT2ATSHRSMN1; SMN2LMNAHTT | |
| SCHEMBL2913766 | 0.90 | TSHR (0.31) | TSHRSMN1; SMN2DDR1 | |
| SCHEMBL2918944 | 0.86 | — | — | |
| SCHEMBL3095577 | 0.85 | DDR1 (0.35) | DDR1 | |
| SCHEMBL2915864 | 0.84 | DDR1 (0.31) | DDR1 | |
| SCHEMBL2912276 | 0.84 | DDR1 (0.34) | ALDH1A1DDR1 | |
| SCHEMBL3099009 | 0.83 | ALDH1A1 (0.30) | TSHRLMNAALDH1A1 | |
| SCHEMBL29558483 | 0.82 | TSHR (0.30) | TSHRSMN1; SMN2 | |
| SCHEMBL1235324 | 0.82 | TSHR (0.30) | TSHRSMN1; SMN2 | |
| SCHEMBL2944425 | 0.82 | CYP17A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648207-B2 | Aryl (1H-1,2,4-triazol-1-yl) compound, and process for production thereof | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8440838-B2 | Aryl (1H-1,2,4-triazol-1-yl) compound and process for production thereof | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130023666-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20100256386-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2226317-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256386-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND AND PROCESS FOR PRODUCTION THEREOF | CYP1A1, CYP2S1, NAT1 | KMT2A 1871/4885TSHR 221/4885SMN1; SMN2 4288/4885 |
| US-20130023666-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | CYP1B1, CYP1A1, AOC3 | KMT2A 3502/4885TSHR 200/4885SMN1; SMN2 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.